Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy) focused on activity, efficacy and safety

Exemestane (Exe) in combination with Everolimus (Eve) represents an important treatment option for patients diagnosed with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (MBC), which was previously treated with non-steroidal aromat...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Wydane w:Mol Clin Oncol
Główni autorzy: Riccardi, Ferdinando, Colantuoni, Giuseppe, Diana, Anna, Mocerino, Carmela, Cartenì, Giacomo, Lauria, Rossella, Febbraro, Antonio, Nuzzo, Francesco, Addeo, Raffaele, Marano, Ombretta, Incoronato, Pasquale, De Placido, Sabino, Ciardiello, Fortunato, Orditura, Michele
Format: Artigo
Język:Inglês
Wydane: D.A. Spandidos 2018
Hasła przedmiotowe:
Articles
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6109668/
https://ncbi.nlm.nih.gov/pubmed/30155246
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2018.1672
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy